ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) is expected to issue its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $0.0940 million for the quarter.
ZIVO Bioscience Trading Up 2.4%
Shares of NASDAQ:ZIVO opened at $10.00 on Friday. The company has a market capitalization of $39.78 million, a price-to-earnings ratio of -2.05 and a beta of 0.19. The firm’s 50-day moving average is $9.27 and its 200 day moving average is $12.05. ZIVO Bioscience has a 12 month low of $6.95 and a 12 month high of $21.00.
ZIVO Bioscience Company Profile
ZIVO Bioscience is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry.
Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development.
Featured Stories
- Five stocks we like better than ZIVO Bioscience
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
